NCT03366506Recruiting
Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)
Source: ClinicalTrials.gov · Last updated 10 Feb 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Investigation of the epidemiological factors associated with amyotrophic lateral sclerosis (ALS) in Israel with a view to future international collaboration. Particularly addressing:- 1. Differences between ethnic subgroups 2. Differences between immigrant and native-born populations 3. Differences according to military service profile Clinical features gathered at each routine visit ,throughout the entire course of the disease, will be recorded in database format, in order to correlate with potential epidemiological factors.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 4 Dec 2017
- Start date
- 9 Mar 2009
- Primary completion date
- 31 Mar 2049
- Lead sponsor
- Hadassah Medical Organization
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT03366506
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 9 Mar 2009 to the primary completion date, 31 Mar 2049
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- \- Suspected, possible, probable ,definite ALS
Age in the registry: 12 years to 120 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hadassah Medical Organisation Coordinator of this site? Confirm its status | Jerusalem | Israel | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.